1. Introduction {#s0005}
===============

Antidepressants are frequently prescribed in the treatment of depression. However, long-term treatment is required for antidepressants to successfully alleviate the symptoms of depression. Individuals who stop antidepressant treatment prematurely may not benefit from treatment and are at a higher risk of relapse ([@bib35; @bib6]). The most common reasons for early discontinuation from antidepressant treatment are adverse effects and lack of efficacy ([@bib4]). It is not currently possible to accurately predict who will discontinue treatment. Variability in antidepressant response has been shown to be influenced by both genetic and environmental factors ([@bib51]) creating the possibility of using genetic biomarkers capable of predicting discontinuation from treatment.

Selective serotonin reuptake inhibitors (SSRIs) are the first choice antidepressant due to their superior adverse effect profile. SSRIs increase the levels of serotonin in the synaptic cleft by binding to the serotonin reuptake transporter (5-HTT), preventing the reuptake and subsequent storage or degradation of serotonin. This leads to the accumulation of serotonin in the synaptic cleft, which in turn may cause adaptive changes in both serotonergic and noradrenergic neurotransmission and downstream neural adaptation, helping to alleviate the symptoms of depression ([@bib12; @bib53]). SSRI-induced side effects may occur when levels of synaptic serotonin increase to an intolerably high concentration resulting in over-stimulation of serotonin receptors in the brain and periphery ([@bib9]).

The serotonin transporter gene-linked polymorphic region (5-HTTLPR) modulates transcriptional activity of 5-HTT. 5-HTTLPR is a 44 base pair insertion--deletion polymorphism which can exist as a long (L) variant of a 16 repeat sequence or a short (S) variant of 14 repeats. The L allele is associated with higher levels of transcription *in vitro* compared to the S allele ([@bib32]). Therefore, the same dose of SSRI may inhibit a higher proportion of 5-HTT in individuals carrying the S allele, causing a rapid accumulation of synaptic serotonin and increasing the risk of adverse effects, potentially leading to discontinuation. As studies have associated 5-HTTLPR with mood disorder ([@bib1; @bib13; @bib22]) and unipolar depression ([@bib3]) it is important to distinguish between genuine pharmacogenetic effects as opposed to effects which simply reflect genotype acting as a marker for disease severity.

The association between 5-HTTLPR and antidepressant treatment has been subject to numerous studies with the majority investigating the outcome of response. In general, data on the number of discontinuations is collected but rarely published with regards to 5-HTTLPR. [@bib36] found that discontinuation rates due to adverse effects were lower in patients of European ancestry receiving paroxetine who were L/L homozygotes. Several studies have reported that patients with an S allele more frequently experience adverse effects during treatment with SSRIs than L allele carriers ([@bib40; @bib34; @bib28]). The largest study to date, using the STAR⁎D cohort, reported that a lesser burden of adverse effects from citalopram treatment was associated with the L allele ([@bib18]). However, the authors reported no evidence of an association between 5-HTTLPR and intolerance (discontinuation with high adverse effect score) to citalopram. The second largest study to date, using the Genome Based Therapeutic Drugs for Depression (GENDEP) cohort, found no evidence of an association between 5-HTTLPR genotype and adverse effects, self-reported adherence or discontinuation with escitalopram or nortriptyline ([@bib19]). Other studies have also failed to find evidence of an association between 5-HTTLPR variants and adverse reactions induced by various SSRIs including fluvoxamine ([@bib48; @bib26]), paroxetine ([@bib27; @bib49]) and sertraline ([@bib38]) or have even reported the SS genotype to be associated with lower rates of agitation compared to those with SL/LL genotype ([@bib29]).

These contradictory findings have possibly occurred because studies *in vivo* have not consistently reported the L allele to be associated with an increase in transporter binding sites ([@bib37]). Other polymorphisms have also been reported to influence gene expression, in particular a single nucleotide polymorphism within the L allele (rs25531). This L~G~ allele may be associated with reduced transporter expression, in a similar manner to the S allele ([@bib17]). Additionally, the role of ancestry may be important. There is a much higher frequency of the S allele in East Asian (79%) than in European (42%) populations ([@bib30]). The difference in allele frequency has the potential to introduce confounding by population structure, as well as reducing the power in studies where the allele frequency is lower. In addition differences in linkage disequilibrium patterns between populations may be important if the SNP which is being studied is a proxy for the one which is influencing outcome.

There have been several meta-analyses attempting to clarify the role of 5-HTTLPR in response to antidepressant treatment. The most recent meta-analysis, which included 33 studies (5479 subjects), concluded that in Europeans 5-HTTLPR may be a predictor of antidepressant response and remission, while in East Asians it does not appear to play a major role ([@bib41]). An earlier meta-analysis which included 28 studies (5408 subjects) concluded that the 5-HTTLPR bi-allelic short/long polymorphism by itself does not seem to predict antidepressant response to a clinically useful degree ([@bib50]). These conflicting findings may be due to the inclusion of different studies as well as stratifying by different factors. A meta-analysis of 9 studies with 2642 participants found that the L allele was associated with a reduced risk of experiencing side effects ([@bib28]).

To build on the work of previous meta-analyses we decided to investigate the association between 5-HTTLPR and the number of individuals who discontinue antidepressant treatment. Our outcome of discontinuation includes individuals who discontinued antidepressant treatment for any reason. We chose our outcome of discontinuation as it does not require an individual to make a potentially complex psychosocial judgement on the reason of discontinuation. Additionally, examining discontinuation is often used to study comparative acceptability of medication ([@bib2]). Ideally our hypothesis would be tested by studying rates of adverse effects but unfortunately not all studies collect this data and exclusion of these studies could introduce bias. Our choice of outcome is clinically important as individuals who discontinue prematurely from antidepressant treatment are unable to benefit from the treatment and are at greater risk of relapse ([@bib35; @bib6]). To our knowledge this is the first meta-analysis to use an outcome of discontinuation from antidepressant treatment.

2. Experimental Procedures {#s0010}
==========================

2.1. Selection of studies for inclusion {#s0015}
---------------------------------------

Studies in which depressed individuals received antidepressant medication and data on discontinuations were reported by 5-HTTLPR polymorphism status were included. The principal outcome measure was the allelic odds ratio (*OR*) for the 5-HTTLPR S allele and discontinuation status. Ancestry was coded as European, East Asian, or other. If the study reported results by ancestry or was a randomised controlled trial (RCT), each population or randomised group was treated as a separate sample.

2.2. Search strategy {#s0020}
--------------------

Electronic databases were searched (Embase, Web of Science and Medline) from the first date available in each database up to 18 September 2012 using the search terms "5-HT", "5-HTT", "SERT", "serotonin", "transporter", "SLC6A4", "5-HTTLPR", "antidepressant", "SSRI", "SRI" or "reuptake inhibitor". The full search strategy is available in Supplementary [Figure 1](#s0090){ref-type="fn"}. Studies were also identified from earlier reviews. Bibliographies of the collected articles were then hand-searched for additional references. The abstracts of the identified studies were then examined with reference to the inclusion and exclusion criteria by two researchers independently. Studies not written in English were translated by a native speaker. Data extraction was also performed by two individuals independently. In cases of disagreement over study eligibility or extraction of data, issues were discussed and a consensus reached. Studies with overlapping patient samples were identified and only the publication with the larger number of patients was included. Authors of published studies were contacted when the necessary data for this meta-analysis were not reported, and included if they provided the data.

2.3. Data analysis {#s0025}
------------------

Data were analysed within a random effects (DerSimonian-Laird) model and the individual and pooled *ORs* and associated 95% confidence intervals (*CI*) were calculated. Random-effects models are more conservative than fixed-effects models and assume that the true effect size could vary from study to study. The significance of the pooled *OR* was determined using a *Z*-test, and heterogeneity between studies was assessed with chi-squared goodness of fit and the *I*^*2*^ statistic. The *I*^*2*^ statistic quantifies the percentage of total variation across studies due to heterogeneity rather than chance variation. The higher the *I*^*2*^ statistic, the more between-study heterogeneity, with the values of 25%, 50%, and 75% considered as low, moderate, and high heterogeneity, respectively ([@bib14]). High between-study heterogeneity indicates potential methodological or sample differences. Our primary analysis compared the effect of the S allele with the L allele on discontinuation, but given the lack of unequivocal data for the 5-HTTLPR genetic model, all models were tested: S allele vs. L allele, S carriers vs. LL, L carriers vs. SS, and SS vs. LL. If data were available, a secondary analysis was performed with an outcome of discontinuation due to adverse effects. We conducted a series of stratified analyses and meta-regression analyses to assess the impact of various study characteristics, including class of antidepressant (SSRI vs. non-SSRI), ancestry (European vs. East Asian vs. Other), year of publication, mean sample age, percentage male, study size and study duration. The genotype distributions for each study were used to calculate deviation from Hardy--Weinberg equilibrium (HWE) using a *χ*^2^ test, and those studies which did show evidence of deviation were excluded in a sensitivity analysis. An influence analysis was also performed to investigate the effects of excluding single studies. To assess potential small study bias, as might be caused by publication bias, a funnel plot was prepared of ln *OR* against the *SE* ln *OR* ([@bib47]) and analysed using Egger\'s test ([@bib8]). An asymmetric funnel plot indicates a relationship between treatment effect and study size. Data were analysed using Stata version 12.1 ([@bib46]). We report exact *p*-values throughout.

3. Results {#s0030}
==========

3.1. Description of studies {#s0035}
---------------------------

A total of 17 studies (longitudinal studies (*n*=11) and RCT\'s (*n*=6)) ([@bib23; @bib7; @bib36; @bib27; @bib26; @bib18; @bib24; @bib25; @bib45; @bib5; @bib10; @bib15; @bib19; @bib42; @bib43; @bib54; @bib11; @bib20; @bib31; @bib44; @bib52; @bib55; @bib21; @bib33; @bib46]), comprising *k*=22 independent samples (each arm of the RCT was treated as a separate sample if the interventions were pharmacologically different and not placebo. Different ancestries were also treated as separate samples) published between 2003 and 2011, were identified by the search strategy and included in the meta-analysis (Supplementary [Figure 2](#s0090){ref-type="fn"}). A total of 4309 individuals (848 discontinuations) were included and samples varied in size from 30 to 980 individuals. The characteristics of these samples are presented in [Table 1](#t0005){ref-type="table"}. Of these, *k*=15 samples were derived from populations of predominantly European ancestry, *k*=4 from populations of East Asian ancestry, and *k*=3 from other populations. The study by [@bib26] only provided genetic data comparing SS homozygotes with L allele carriers and so had to be excluded from other analyses. All studies included individuals with a diagnosis of depression, however one study looked at depressed patients after brain trauma ([@bib31]), and one study also included individuals with bipolar disorder ([@bib45]). The study by [@bib45] and a sample from the study by [@bib18] deviated from HWE (*p*=0.03 and *p*\<0.001, respectively).

3.2. Meta-analysis {#s0040}
------------------

### 3.2.1. Exploratory analysis {#s0045}

A total of 22 independent samples (4309 individuals in total: The "SSRI" antidepressant analysis included 16 samples and 3311 individuals; the "other" antidepressants analysis included 6 samples and 998 individuals) were included. We found no evidence that the S allele was associated with discontinuation from antidepressant treatment overall (*OR* 0.95, 95% CI 0.79--1.14, *p*=0.55) or in the sub-group analyses in the SSRI group (*OR* 0.98, 95% CI 0.77--1.24, *p*=0.83) or other antidepressant group (*OR* 0.88, 95% CI 0.72--1.09, *p*=0.24). There was evidence of moderate heterogeneity (*χ*^*2*^~\[20\]~=41.67, *p*=0.003, *I*^*2*^=52%) which remained when the SSRI group was considered separately (*χ*^*2*^~\[14\]~=34.65, *p=*0.002, *I*^*2*^=60%). Analysis by different genotype models did not substantially alter the results (results available on request). Excluding any individual study, any study not in HWE ([@bib18; @bib45]), or any study including depressed individuals with another diagnosed disorder ([@bib45; @bib31]), did not alter our results substantially.

### 3.2.2. Analysis in European individuals {#s0050}

A total of 15 independent samples (3367 individuals in total: 10 samples and 2504 individuals included in the "SSRI" antidepressant analysis; 5 samples and 863 individuals included in the "other" antidepressants analysis) were included. We found no evidence that the S allele was associated with increased odds of discontinuation from antidepressant treatment overall (*OR* 1.00, 95% CI 0.81--1.22, *p*=0.96) or in the SSRI group (*OR* 1.09, 95% CI 0.83--1.42, *p*=0.53) or other antidepressant group (*OR* 0.86, 95% CI 0.68--1.09, *p*=0.22). There was evidence of moderate heterogeneity (*χ*^*2*^~\[14\]~=30.14, *p*=0.007, *I*^*2*^=54%) which remained when the SSRI group was considered separately (*χ*^*2*^~\[9\]~=22.22, *p*=0.008, *I*^*2*^=60%). These results are displayed graphically in [Figure 1](#f0005){ref-type="fig"}. Analysis by different genotype models did not substantially alter the results (Supplementary [Figures 3--5](#s0090){ref-type="fn"}). Excluding any individual study, any study not in HWE or any study not exclusively of depressed individuals did not alter our results substantially.

### 3.2.3. Analysis in East Asian individuals {#s0055}

A total of 4 independent samples (371 individuals in total: 3 samples and 236 individuals included in the "SSRI" antidepressant analysis; 1 sample and 135 individuals included in the "other" antidepressants analysis) were included. The study by [@bib26] only provided genetic data in a format that allowed inclusion in the analysis comparing SS homozygotes with L allele carriers (SS vs. SL/LL). We found evidence that the S allele (S vs. L) was associated with reduced odds of discontinuation from SSRI treatment (*OR* 0.28, 95% CI 0.12--0.64, *p*=0.002; [Figure 1](#f0005){ref-type="fig"}). Comparing homozygote individuals (SS vs. LL) did not alter results substantially. There was weak statistical evidence of an association when comparing SS homozygotes with L allele carriers (*OR* 0.34, *p*=0.08), and when comparing LL homozygotes with S allele carriers (LL vs. SL/SS) (*OR* 0.24, *p*=0.14).

### 3.2.4. Discontinuation due to adverse effects {#s0060}

We investigated an outcome of discontinuations specifically due to adverse effects in Europeans receiving SSRI treatment (5 independent samples ([@bib36; @bib18; @bib5; @bib42; @bib20]), 1307 individuals were included). A per allele analysis found no evidence of an association (OR 1.43, 95% CI 0.74--2.76, *p=*0.3; data available by request).

### 3.2.5. Small study bias {#s0065}

Visual inspection of a funnel plot of all studies indicated asymmetry, suggesting that some small studies reporting an association between the S allele and increased risk of discontinuation may be missing (Supplementary [Figure 6](#s0090){ref-type="fn"}). Egger\'s test provided some evidence of small study bias (*p*=0.05) when all studies were included, although this test has low statistical power given the small number of studies. Evidence of small study bias no longer remained when only European studies were included (*p*=0.34). There was no evidence between individual study effect size estimate and year of publication (*p*=0.55), mean sample age (*p*=0.91), study size (*p*=0.32), percentage male (*p*=0.55) or study duration (*p*=0.30) when all studies were included, or when restricted to European only studies (results available on request).

4. Discussion {#s0070}
=============

To our knowledge, this is the first meta-analysis to assess the association of 5-HTTLPR genotype with discontinuation following SSRI treatment. Our results find no evidence of an association between 5-HTTLPR and discontinuation from SSRI treatment in a European population. This supports the findings from the three largest studies on a predominantly European population (STAR\*D ([@bib18]), GENDEP ([@bib19]) and Genetic and clinical Predictors Of treatment response in Depression (GENPOD) ([@bib33])), suggesting that there is no evidence of an association between the bi-allelic 5-HTTLPR polymorphism with SSRI discontinuation in Europeans. However, due to the low number of discontinuation events we are unable to rule out the possibility of a clinically important effect with SSRI treatment as the S allele may be associated with up to a 42% increase in odds of discontinuation or a 17% reduced odds (*OR* 1.09, 95% CI 0.83--1.42).

We found some evidence that the S allele decreases the odds of discontinuation from SSRI treatment in East Asians. The low number and small size of East Asian studies (only 17 dropouts in the SSRI analysis) included in this meta-analysis mean that further studies are required to investigate its effects before we can draw any firm conclusions. There was evidence of considerable heterogeneity even within Europeans treated with an SSRI. The cause of this heterogeneity is unknown as there was substantial consistency in the diagnostic criteria as well as antidepressant agents used.

This meta-analysis investigated the 5-HTTLPR as a bi-allelic polymorphism only. Ideally polymorphisms such as rs25531 and VNTR STin2 should be included as these have also been reported to affect gene expression ([@bib16]), although the functionality of some of these variants remains uncertain ([@bib39]). Other polymorphisms were not included in this meta-analysis as not all studies have the necessary genetic data. From our 17 studies only 6 had the necessary genetic data for rs25531, and exclusion of the other studies would result in loss of power and could introduce bias. The largest study to date reported an analysis in which individuals were differentiated according to the presence of the L~A~ allele, this stratification did not substantially alter results when analysing the whole STAR\*D sample. However, it did alter the results of a sub-group analysis of white, non-Hispanic individuals with adverse effect burden as the outcome ([@bib18]).

Commonly cited reasons for discontinuing antidepressant treatment are due to adverse effects or lack of efficacy. The evidence from the two most recent meta-analyses investigating these outcomes (adverse effects ([@bib28]), response ([@bib41])) suggests that the L allele is associated with a reduced risk of experiencing adverse effects, and with increased odds of responding to SSRI treatment. However, we found no evidence for an association between the L allele and reduced odds of discontinuation. There are multiple reasons why an individual may choose to stop antidepressant treatment, not associated with antidepressant response or adverse effects, such as fear of drug dependency. Therefore, our outcome of all discontinuations may have been too broad to find evidence of an association with 5-HTTLPR. However, our analysis of discontinuation due to adverse effects also found no evidence of an association with 5-HTTLPR. The low number of independent samples with data on reason of discontinuation mean this analysis lacked the power to detect a potentially important effect and further work could focus on discontinuation specifically due to adverse effects or lack of efficacy.

As mentioned previously the low number of Asian studies included in this meta-analysis mean we are currently unable to determine the effect of this polymorphism in an East Asian population. However, the results of this meta-analysis summarise the available data on SSRI-discontinuation and 5-HTTLPR in a European population. At present, there is no evidence of an association between 5-HTTLPR and discontinuation from SSRI treatment in a European population. The lack of precision in our effect estimate (indicated by our wide 95% CI) highlights the need for greater research in this area before we can make any definite conclusions on its potential clinical importance. A meta-analysis of approximately 5400 European individuals would be required to determine whether 5-HTTLPR has at least a 15% change in risk of discontinuation from SSRI treatment. Future studies should report adverse effects and discontinuation alongside the more customary efficacy measurements in order to improve our knowledge of the 5-HTTLPR and its effect on outcomes following antidepressant treatment.
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![Meta-analysis of association studies of 5-HTTLPR genotype and SSRI discontinuation stratified by ancestry (European vs. East Asian vs. Other). Meta-analysis provides no evidence of an association between 5-HTTLPR genotype and SSRI discontinuation for European studies (*z*=0.63, *p*=0.53) for other studies (*z*=0.51, *p*=0.61), or overall (*z*=0.21, *p*=0.8). There is evidence of an association between 5-HTTLPR genotype and SSRI discontinuation for East Asian studies (*z*=3.03, *p*=0.002). Bars represent individual study 95% confidence intervals, with a central block proportional to study size. The summary diamond bars represent the pooled effect size estimate and 95% confidence interval (CI) for the European studies, East Asian studies, other studies and all studies, as you look from top to bottom.](gr1){#f0005}

###### 

Characteristics and summary of results of included samples.

  **Sample**           **Year**   **Sample size**   **No. of dropouts**   **SS (%)**   **Antidepressant**                    **Ancestry**   **Mean Age**   **Male (%)**   **HWE**
  -------------------- ---------- ----------------- --------------------- ------------ ------------------------------------- -------------- -------------- -------------- ---------
  Joyce (38)           2003       86                11                    34           Fluoxetine                            European       32             44             Yes
  Joyce (38)           2003       82                25                    27           Nortriptyline                         European       32             44             Yes
  Murphy (13)          2004       121               30                    20           Paroxetine                            European       72             47             Yes
  Murphy (13)          2004       123               18                    25           Mirtazapine                           European       72             50             Yes
  Durham (36)          2004       101               20                    16           Sertraline                            European       70             47             Yes
  Kato (20)            2006       100               20                    60           Paroxetine, Fluvoxamine               East Asian     44             56             Yes
  Hu (17)              2007       420               64                    21           Citalopram                            Other          42             39             No
  Hu (17)              2007       980               137                   18           Citalopram                            European       42             39             Yes
  Kang (48)            2007       135               34                    76           Mirtazapine                           East Asian     50             29             Yes
  Serretti (44)        2007       281               86                    24           Fluvoxamine, Paroxetine, Sertraline   European       49             32             No
  Dogan (39)           2008       64                20                    33           Sertraline                            European       37             22             Yes
  Yoshimura (42)       2009       71                11                    35           Paroxetine                            East Asian     44             44             Yes
  Huezo-Diaz (18)      2009       450               92                    17           Escitalopram                          European       43             38             Yes
  Huezo-Diaz (18)      2009       345               94                    15           Nortriptyline                         European       42             35             Yes
  Ruhe (43)            2009       51                7                     16           Paroxetine                            European       42             36             Yes
  Lewis (35)           2010       273               41                    19           Citalopram                            European       39             36             Yes
  Lewis (35)           2010       283               93                    17           Reboxetine                            European       39             34             Yes
  Illi (37)            2010       97                12                    13           Citalopram, Fluoexetine, Paroxetine   European       42             42             Yes
  Yuksel (41)          2010       30                10                    27           Venlafaxine                           European       37             43             Yes
  Umene-Nakano (45)    2010       65                6                     60           Sertraline                            East Asian     55             37             Yes
  Lanctot (46)         2010       79                9                     30           Citalopram                            Other          40             56             Yes
  Gudayol Ferre (47)   2010       72                8                     39           Fluoxetine                            Other          31             8              Yes

Characteristics of included samples is presented, with year, number of subjects, number of discontinuations, percentage (%) of individuals homozygous with the short (S) 5-HTTLPR allele, type of antidepressant, sample ancestry, mean age, percentage of males in the sample, and whether the genotype frequencies reported were in approximate Hardy--Weinberg Equilibrium (HWE).
